Skip to main content

FDA Drug Recalls

Every FDA drug enforcement recall Public Health Trace has on record, republished from openFDA's official drug enforcement database. See Health Alerts for current, active recalls alongside outbreaks and advisories.

Drug recall information is sourced from the FDA's structured openFDA Enforcement Reports. Newly announced recalls may appear on FDA.gov before they become available in the structured dataset. See Methodology for how Public Health Trace imports and refreshes this data.

Filters
Recall details
Location
Date range
Clear filters

Showing 3,581–3,600 of 17,937 drug recalls

Drug Recall Terminated Historical recordClass II

Divalproex Sodium Delayed-Release Tablets, USP 500mg, Rx Only, 100 Tablets, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Industries, Ltd., Halol-Baroda Highway, Halol- 389 350, Gujarat, India, NDC 62756-798-88.

by SUN PHARMACEUTICAL INDUSTRIES INC

Reason
Failed Dissolution Specifications: Failure occurred during routine stability testing of dissolution test.
Recall initiated
June 27, 2022
Reported by FDA
August 3, 2022
Distribution
Nationwide in the USA

View recall →

Drug Recall Completed Historical recordClass III

Crest 3D White Fluoride Anticavity Toothpaste, Advanced Triple Whitening, 0.243% sodium fluoride, Net Wt. 5.6 oz (158 g) a) Individual carton, UPC 0 37000 598534; b) 5-count Bundle, UPC 037000171867, Distributed. By Procter & Gamble, Cincinnati, OH 45202.

by The Procter & Gamble Company

Reason
Labeling: Missing label: the product tube was missing a label and contained a different formulation.
Recall initiated
July 8, 2022
Reported by FDA
August 3, 2022
Distribution
Washington State

View recall →

Drug Recall Terminated Historical recordClass II

Testosterone Gel 1% (25mg testosterone/2.5g of gel) 2.5 g per unit dose, Rx Only, 30 unit-dose packets per box. Manufactured by: Actavis Laboratories UT, Inc., Salt Lake City, US 84108, USA, Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054, USA, Sachet NDC 0591-3216-17, Carton NDC 0591-3216-30

by Teva Pharmaceuticals USA Inc

Reason
Superpotent Drug: Out of specification assay result was obtained during stability testing.
Recall initiated
June 29, 2022
Reported by FDA
August 3, 2022
Distribution
Nationwide in the USA

View recall →

Drug Recall Terminated Historical recordClass II

Lansoprazole Delayed-Release Orally Disintegrating Tablets, 35 mg, 100-count blisters per carton, 10 Packs of 10 Tablets Each, Rx Only, Distributed by: Dr. Reddy's Laboratories, Inc., Princeton, NJ 08540, Made in India, blister barcode 4359856179, NDC 43598-561-78

by Dr. Reddy's Laboratories, Inc.

Reason
FAILED DISSOLUTION SPECIFICATIONS
Recall initiated
July 13, 2022
Reported by FDA
August 3, 2022
Distribution
Nationwide in the USA

View recall →

Drug Recall Terminated Historical recordClass II

Lansoprazole Delayed-Release Orally Disintegrating Tablets, 15 mg, 100-count blisters per carton, 10 Packs of 10 Tablets Each, Rx Only, Distributed by: Dr. Reddy's Laboratories, Inc., Princeton, NJ 08540, Made in India, blister barcode 4359856079, NDC 43598-560-78

by Dr. Reddy's Laboratories, Inc.

Reason
FAILED DISSOLUTION SPECIFICATIONS
Recall initiated
July 13, 2022
Reported by FDA
August 3, 2022
Distribution
Nationwide in the USA

View recall →

Drug Recall Terminated Historical recordClass I

Nifedipine WSP 0.2% Ointment, 60 gram tubes, Rx only, Valor Compounding Pharmacy, 2461 Shattuck Ave., Berkeley, CA 94704

by Valor Compounding Pharmacy, Inc DBA Valor Compounding Pharmacy

Reason
Subpotent and Superpotent Drug
Recall initiated
June 27, 2022
Reported by FDA
August 3, 2022
Distribution
CA only

View recall →

Drug Recall Terminated Historical recordClass II

Launch Sequence Aphrodisia Capsules, 4-count tins, ASIN B07QB3S2LV, UPC Code 661020846957.

by Loud Muscle Science

Reason
Marketed Without An Approved NDA/ANDA: Unapproved Drug based on label claims.
Recall initiated
June 27, 2022
Reported by FDA
July 27, 2022
Distribution
The product was distributed nationwide in the USA and Canada.

View recall →

Drug Recall Terminated Historical recordClass II

Launch Sequence Euphoria Capsules, 10- count tins, ASIN B08ZJX4V9J, UPC Code 661020846864.

by Loud Muscle Science

Reason
Marketed Without An Approved NDA/ANDA: Unapproved Drug based on label claims.
Recall initiated
June 27, 2022
Reported by FDA
July 27, 2022
Distribution
The product was distributed nationwide in the USA and Canada.

View recall →

Drug Recall Terminated Historical recordClass II

Launch Sequence Capsules, Dietary Supplement, 60- count bottles, ASIN B07TLPWXDS, UPC Code 641378938375.

by Loud Muscle Science

Reason
Marketed Without An Approved NDA/ANDA: Unapproved Drug based on label claims.
Recall initiated
June 27, 2022
Reported by FDA
July 27, 2022
Distribution
The product was distributed nationwide in the USA and Canada.

View recall →

Drug Recall Terminated Historical recordClass I

Launch Sequence Aphrodisia Capsules, 4-count tins, ASIN B07QB3S2LV, UPC Code 661020846957.

by Loud Muscle Science

Reason
Marketed Without An Approved NDA/ANDA: Product found to contain undeclared tadalafil, an ingredient found in FDA approved products for the treatment of male sexual enhancement, making this an unapproved drug.
Recall initiated
June 27, 2022
Reported by FDA
July 27, 2022
Distribution
The product was distributed nationwide in the USA and Canada.

View recall →

Drug Recall Terminated Historical recordClass I

Launch Sequence Euphoria Capsules, 10- count tins, ASIN B08ZJX4V9J, UPC Code 661020846864.

by Loud Muscle Science

Reason
Marketed Without An Approved NDA/ANDA: Product found to contain undeclared tadalafil, an ingredient found in FDA approved products for the treatment of male sexual enhancement, making this an unapproved drug.
Recall initiated
June 27, 2022
Reported by FDA
July 27, 2022
Distribution
The product was distributed nationwide in the USA and Canada.

View recall →

Drug Recall Terminated Historical recordClass I

Launch Sequence Capsules, Dietary Supplement, 60- count bottles, ASIN B07TLPWXDS, UPC Code 641378938375.

by Loud Muscle Science

Reason
Marketed Without An Approved NDA/ANDA: Product found to contain undeclared tadalafil, an ingredient found in FDA approved products for the treatment of male sexual enhancement, making this an unapproved drug.
Recall initiated
June 27, 2022
Reported by FDA
July 27, 2022
Distribution
The product was distributed nationwide in the USA and Canada.

View recall →

Drug Recall Terminated Historical recordClass I

Artri King Reforzado con Ortiga y Omega 3 tablets, 500 mg, 100-count bottle, Hecho en Mexico por: PLANTAS MEDICINALES DE MEXICO , Melchor Ocampo No. 55 Local D, Delegacion Xochimilco. C.P. 16800, Mexico, D.F., ASIN B084KSV12L, UPC 7 501031 111190

by Amazon.com, Inc.

Reason
Marketed Without An Approved NDA/ANDA: FDA laboratory analysis found the product to contain undeclared diclofenac.
Recall initiated
May 26, 2022
Reported by FDA
July 27, 2022
Distribution
Nationwide within the U.S.A.

View recall →

Drug Recall Terminated Historical recordClass I

Ortiga mas Ajo Rey Reforzado con Omega 3, 6 y 9, is packaged in a carton containing 30 tablets (500 mg c/u) in a bottle and 60 capsules (400 mg c/u) in a bottle, Hecho en Mexico por: Omega Nutrition , Jorge Washington No. 108 Col. Las Americas, Hidalgo del Parral, Chihuahua. C.P. 33880, ASIN B084L2XM3Z, UPC 3166557819586

by Amazon.com, Inc.

Reason
Marketed Without An Approved NDA/ANDA: FDA laboratory analysis found the product to contain undeclared diclofenac.
Recall initiated
May 26, 2022
Reported by FDA
July 27, 2022
Distribution
Nationwide within the U.S.A.

View recall →

Drug Recall Terminated Historical recordClass I

Artri Ajo King Reforzado con Ortiga y Omega 3 tablets, 500 mg, 100-count bottle, Hecho en Mexico por: PLANTAS MEDICINALES DE MEXICO , Melchor Ocampo No. 55 Local D, Delegacion Xochimilco. C.P. 16800, Mexico, D.F., ASIN B092P4615M, UPC 7 501031 111190

by Amazon.com, Inc.

Reason
Marketed Without An Approved NDA/ANDA: FDA laboratory analysis found the product to contain undeclared diclofenac.
Recall initiated
May 26, 2022
Reported by FDA
July 27, 2022
Distribution
Nationwide within the U.S.A.

View recall →

Drug Recall Terminated Historical recordClass II

Aripiprazole Tablets, USP 20 mg, packaged in a) 1,000-count bottle (NDC 60505-2676-8, UPC 3 60505 26768 2), b) 30-count bottle (NDC 60505-2676-3, UPC 3 60505 26763 7), Rx only, Manufactured by: Apotex, Inc. Toronto, Ontario Canada M9L 1T9 Manufactured for: Apotex Corp. Weston, Florida 33326

by Apotex Corp.

Reason
Failed dissolution specifications: OOS for dissolution at the 12-month stability time point.
Recall initiated
July 7, 2022
Reported by FDA
July 27, 2022
Distribution
USA Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

Difluprednate Ophthalmic Emulsion, 0.05%, 5ml bottles, Rx only, Mfd. by: Cipla Ltd., India At M/S Indoco Remedies Limited., L-32, 33, 34, Verna Industrial area, Verna - Goa, 403722, India; Mfd. for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, NDC 69097-341-35.

by CIPLA

Reason
Lack of Assurance of Sterility: customer complaint for defective container where breakage of the protective cap exposes tip of eye drop which could compromise sterility.
Recall initiated
July 14, 2022
Reported by FDA
July 27, 2022
Distribution
Nationwide in the USA

View recall →

Drug Recall Ongoing Historical recordClass III

Aspirin and Extended-Release Dipyridamole Capsules, 25mg/200 mg, 60-count bottle, Rx Only, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, Product of India, NDC 68462-405-60.

by Glenmark Pharmaceuticals Inc., USA

Reason
Failed Tablet/Capsule Specification : Capsule breakage
Recall initiated
June 29, 2022
Reported by FDA
July 27, 2022
Distribution
USA Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

Succinylcholine Chloride Injection, USP, 200 mg/10 mL (20 mg/mL) syringe, packaged in 5 x 10 mL Pre-Filled Syringes per carton, 6 x 5 Syringe Carton per case, Rx Only, Nephron 503B outsourcing facility, 4500 12th St. Extension, West Columbia, SC 29172, NDC: 69374-919-10

by Nephron Sterile Compounding Center LLC

Reason
Lack of Assurance of Sterility
Recall initiated
June 30, 2022
Reported by FDA
July 27, 2022
Distribution
Nationwide in the USA

View recall →

Drug Recall Terminated Historical recordClass II

Anticoagulant Sodium Citrate Solution, USP 4%, 200 mg/5 mL (40 mg/mL) syringe, packaged in 5 x 5 mL Pre-Filled Syringes per carton, 6 x 5 Syringe Carton per case, Rx Only, Nephron 503B outsourcing facility, 4500 12th St. Extension, West Columbia, SC 29172, NDC: 69374-906-05

by Nephron Sterile Compounding Center LLC

Reason
Lack of Assurance of Sterility
Recall initiated
June 30, 2022
Reported by FDA
July 27, 2022
Distribution
Nationwide in the USA

View recall →

Data last updated:

This information is republished from FDA's Recall Enterprise System through openFDA. Public Health Trace does not verify or supplement it, is not affiliated with the FDA, and does not provide medical advice -- always follow the guidance of your pharmacist, physician, or the recalling company for any medication you take. Read the full medical disclaimer.